Secondary hyperparathyroidism (SHPT) is often observed in patients with end-stage renal disease (ESRD) and can result in excessive parathyroid hormone (PTH) secretion, leading to osteodystrophy, bone fractures, and increased risks of mortality and cardiovascular events (1–4). Here, PTH is linked to stage 5 chronic kidney disease.